Details for Patent: 10,065,958
✉ Email this page to a colleague
Which drugs does patent 10,065,958 protect, and when does it expire?
Patent 10,065,958 protects VEKLURY and is included in one NDA.
Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-eight patent family members in thirty-one countries.
Summary for Patent: 10,065,958
| Title: | Methods and compounds for treating Paramyxoviridae virus infections |
| Abstract: | Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections. |
| Inventor(s): | Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US14/613,719 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,065,958 |
|
Patent Claim Types: see list of patent claims | Compound; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 10,065,958
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | 10,065,958*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | DISCN | Yes | No | 10,065,958*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,065,958
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2595980 | ⤷ Start Trial | 132020000000176 | Italy | ⤷ Start Trial |
| European Patent Office | 2595980 | ⤷ Start Trial | 122020000084 | Germany | ⤷ Start Trial |
| European Patent Office | 2595980 | ⤷ Start Trial | 301084 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2595980 | ⤷ Start Trial | 2020C/554 | Belgium | ⤷ Start Trial |
| European Patent Office | 2595980 | ⤷ Start Trial | 53/2020 | Austria | ⤷ Start Trial |
| European Patent Office | 2595980 | ⤷ Start Trial | C02595980/01 | Switzerland | ⤷ Start Trial |
| European Patent Office | 2595980 | ⤷ Start Trial | C202030068 | Spain | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
